Laguna, M. P. et al. EAU guidelines on testicular cancer. EAU https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Testicular-Cancer-2022.pdf (2022).
Cheng, L. et al. Testicular cancer. Nat. Rev. Dis. Primers 4, 29 (2018).
Oldenburg, J. et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24, vi125–vi132 (2013).
International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a. prognostic factor-based staging system for metastatic germ cell. J. Clin. Oncol. 15, 594–603 (1997).
Gillessen, S. et al. Redefining the IGCCCG classification in advanced non-seminoma [abstract 903O]. Ann. Oncol. 30 (Suppl. 5), v357–v358 (2019).
Gilligan, T. et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 17, 1529–1554 (2019).
Cancer Research UK. Testicular cancer incidence statistics. Cancer Research UK https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/testicular-cancer/incidence (2022).
Williams, S. D. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316, 1435–1440 (1987).
Article CAS PubMed Google Scholar
Travis, L. B. et al. Testicular cancer survivorship: research strategies and recommendations. J. Natl Cancer Inst. 102, 1114–1130 (2010).
Article PubMed PubMed Central Google Scholar
Meinardi, M. T. et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 18, 1725–1732 (2000).
Article CAS PubMed Google Scholar
Fung, C. et al. Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors. Adv. Urol. 2018, 8671832 (2018).
Article PubMed PubMed Central Google Scholar
Amin, M. B. et al. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 267, 93–99 (2017).
Fosså, S. D. et al. Mortality and second cancer incidence after treatment for testicular cancer: psychosocial health and lifestyle are modifiable prognostic factors. J. Clin. Oncol. 40, 2588–2599 (2022).
O’Sullivan, J. M. et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol. 14, 91–96 (2003).
Simpson, A. B., Paul, J., Graham, J. & Kaye, S. B. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br. J. Cancer 78, 1061–1066 (1998).
Article CAS PubMed PubMed Central Google Scholar
Haugnes, H. S. et al. Pulmonary function in long-term survivors of testicular cancer. J. Clin. Oncol. 27, 2779–2786 (2009).
Haugnes, H. S., Oldenburg, J. & Bremnes, R. M. Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urol. Oncol. 33, 399–406 (2015).
Sleijfer, S. Bleomycin-induced pneumonitis. Chest 120, 617–624 (2001).
Article CAS PubMed Google Scholar
Ehrlich, Y., Margel, D., Lubin, M. A. & Baniel, J. Advances in the treatment of testicular cancer. Transl. Androl. Urol. 4, 381–390 (2015).
PubMed PubMed Central Google Scholar
Huddart, R. A. et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21, 1513–1523 (2003).
Article CAS PubMed Google Scholar
Van Den Belt-Dusebout, A. W. et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol. 25, 4370–4378 (2007).
Fosså, S. D., Aass, N., Winderen, M., Börmer, O. P. & Olsen, D. R. Long-term renal function after treatment for malignant germ-cell tumours. Ann. Oncol. 13, 222–228 (2002).
Hansen, S. W., Groth, S., Daugaard, G., Rossing, N. & Rørth, M. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J. Clin. Oncol. 6, 1728–1731 (1988).
Article CAS PubMed Google Scholar
Kennedy, I. C., Fitzharris, B. M., Colls, B. M. & Atkinson, C. H. Carboplatin is ototoxic. Cancer Chemother. Pharmacol. 26, 232–234 (1990).
Article CAS PubMed Google Scholar
Hjelle, L. V. et al. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urol. Oncol. 34, 487.e13–487.e20 (2016).
Article CAS PubMed Google Scholar
Kerns, S. L. et al. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J. Clin. Oncol. 36, 1505–1512 (2018).
Article CAS PubMed PubMed Central Google Scholar
Brydøy, M. et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur. Urol. 58, 134–141 (2010).
Brydøy, M. et al. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br. J. Cancer 107, 1833–1839 (2012).
Article PubMed PubMed Central Google Scholar
Brydøy, M. et al. Paternity following treatment for testicular cancer. J. Natl Cancer Inst. 97, 1580–1588 (2005).
Loren, A. W. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31, 2500–2510 (2013).
Article PubMed PubMed Central Google Scholar
Giannatempo, P. et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann. Oncol. 26, 657–668 (2015).
Article CAS PubMed Google Scholar
Hanna, N. et al. in Holland-Frei Cancer Medicine 6th edn (eds Kufe, D. W. et al.) (BC Decker, 2003).
Travis, L. B. et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J. Natl Cancer Inst. 97, 1354–1355 (2005).
Hellesnes, R. et al. Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort [abstract]. J. Clin. Oncol. 39 (Suppl. 15), 5006 (2021).
Honecker, F. et al. ESMO consensus conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann. Oncol. 29, 1658–1686 (2018).
Article CAS PubMed Google Scholar
Spinner, M. A. & Advani, R. H. Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2018, 200–206 (2018).
Article PubMed PubMed Central Google Scholar
Grimison, P. S. et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J. Natl Cancer Inst. 102, 1253–1262 (2010).
Article CAS PubMed Google Scholar
Nichols, C. & Kollmannsberger, C. Alternatives to standard BEP × 3 in good-prognosis germ cell tumors – you bet your life. J. Natl Cancer Inst. 102, 1214–1215 (2010).
Newton, C. et al. A multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice. Eur. J. Cancer 113, 19–27 (2019).
Article CAS PubMed PubMed Central Google Scholar
Tookman, L. et al. Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma. Acta Oncol. 52, 987–993 (2013).
Article CAS PubMed Google Scholar
Powles, T. et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann. Oncol. 19, 443–447 (2008).
Article CAS PubMed Google Scholar
Horwich, A. et al. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J. Clin. Oncol. 7, 1150–1156 (1989).
Article CAS PubMed Google Scholar
Shamash, J. et al. A phase II study of carboplatin AUC-10 guided by positron emission tomography-defined metabolic response in metastatic seminoma. Eur. J. Cancer 115, 128–135 (2019).
留言 (0)